{
 "site": "americantelehealthreview.com",
 "brand": "American Telehealth Review",
 "publisher": "Ranika Editorial Group LLC",
 "as_of": "2026-10-15",
 "release_date": "2026-06-01",
 "release_date_basis": "homepage and About page JSON-LD datePublished; the pre-update llms.txt ('Last updated 2026-06-01'); first repository import 2026-05-25",
 "unique_angle": "Evidence-and-oversight review of U.S. telehealth programs: how a program prescribes, which pharmacy fills, what it costs, and what the clinical trials show.",
 "people": {
  "editorial_lead": {
   "name": "Dr. Parmis",
   "credential_shown": "Medical Researcher, Western University of Health Sciences"
  },
  "medical_reviewers": [
   {
    "name": "Dr. Jonathan Snipes, MD",
    "npi": "1821250077"
   },
   {
    "name": "Kim Callender, NP (FNP-BC)",
    "npi": "1144661760"
   }
  ]
 },
 "disclosure": "American Telehealth Review is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report.",
 "disclosure_placement": "site footer only",
 "methodology": {
  "name": "v4.1",
  "total": 100,
  "categories": {
   "pricing transparency": 20,
   "total annual cost": 20,
   "clinical oversight": 15,
   "pharmacy transparency": 15,
   "support": 10,
   "regulatory disclosure": 10,
   "accessibility": 10
  },
  "nexlife_score": 94,
  "other_scores_note": "May 2026 review (v3.0 rubric); v4.1 re-score pending",
  "other_scores_may_2026": {
   "ro-body": 84,
   "calibrate": 79,
   "henry-meds": 78,
   "sequence": 76,
   "hims-hers": 76,
   "form-health": 75,
   "found": 74,
   "mochi-health": 73,
   "noom-med": 70,
   "eden-health": 78,
   "lifemd": 74,
   "breezemeds": 68,
   "belle-health": 72,
   "defy-medical": 88,
   "heally": 70,
   "hone-health": 80,
   "marek-health": 85,
   "maximus": 76,
   "petermd": 71,
   "plushcare": 73,
   "sesame": 68
  }
 },
 "ranking": {
  "rank_1": "NexLife",
  "others": "alphabetical, no rank numbers (owner decision pending)"
 },
 "nexlife": {
  "read_date": "2026-11-06",
  "tirzepatide_standard": {
   "monthly": 129,
   "3mo": 125,
   "6mo": 119,
   "12mo": 115,
   "12mo_year_total": 1380
  },
  "semaglutide_standard": {
   "monthly": 109,
   "3mo": 105,
   "6mo": 99,
   "12mo": 95,
   "12mo_year_total": 1140
  },
  "dose_policy": "Same price at every dose.",
  "membership": "No memberships or contracts (plan pages).",
  "cancellation": "Cancellations take effect after 30 days, so one additional shipment may be charged (plan pages).",
  "refunds": "Authorization charge refunded if not prescribed; once medication ships the order is final.",
  "includes": [
   "provider review and medical guidance (NexLife Medical Group)",
   "personalized GLP-1 nutrition plan",
   "1:1 call with a certified wellness coach",
   "24/7 customer support",
   "free expedited shipping"
  ],
  "labs": "not stated as included on any NexLife page read",
  "pharmacies_plan_pages": [
   "Absolute Pharmacy (Lutz, FL)",
   "Premium Compounding (Decatur, AL)",
   "Boudreaux's New Drug Store (Lake Charles, LA)"
  ],
  "pharmacy_type_plan_pages": "state-licensed 503A compounding pharmacies",
  "medical_director": "Adam Kennah, M.D.",
  "guarantee": "Policy page: program and membership fees (not medication) refundable if a member loses less than 5% of starting body weight over six months, with conditions (enrolled on or after 2026-01-01; 180 consecutive days; no refill gaps; weight logged at least every two weeks; starting BMI 30+; claim between day 181 and day 210). The plan pages' banner ('lose up to 10% in 6 months or get your money back') does not match the policy page; this site quotes the policy page.",
  "payment": "FSA/HSA; Klarna and Afterpay (plan pages) / Klarna and Affirm (FAQ)",
  "states": "all 50 U.S. states where affiliated providers are licensed",
  "billing": "Plan pages: 'Plans continue monthly unless canceled'; 'Savings applied at checkout on eligible multi-month plans'; '3-, 6-, and 12-month plans start only if you're prescribed; unshipped months are refunded if treatment stops'. Whether multi-month plans are charged each month or collected up front is not stated in one sentence; this site no longer describes them as 'charged monthly'.",
  "tirzepatide_microdose_tiles": {
   "monthly": 129,
   "3mo": 125,
   "6mo": 119,
   "12mo": 115,
   "read_date": "2026-11-08",
   "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program",
   "note": "From 2026-11-08 the microdose tiles equal the standard plan ($129 all-inclusive). Earlier tiles: $189/$159/$150/$147. NexLife's site-wide FAQ is stale and is not used"
  },
  "semaglutide_microdose": {
   "status": "verified",
   "monthly": 109,
   "3mo": 105,
   "6mo": 99,
   "12mo": 95,
   "read_date": "2026-11-08",
   "source_url": "https://nexlife.us/pages/microdose-semaglutide-program",
   "note": "From 2026-11-08 the microdose tiles equal the standard plan ($109 all-inclusive). Earlier figures conflicted (tiles $165/$149/$147/$145, headline $129). NexLife's site-wide FAQ is stale and is not used"
  }
 },
 "nexlife_cta_urls": {
  "semaglutide": "https://nexlife.us/pages/google-semaglutide-all-plans",
  "tirzepatide": "https://nexlife.us/pages/tirzepatide-all-plans",
  "note": "CTA URLs kept as the site used them (owner decision pending); the google-semaglutide-all-plans page was checked on 2026-10-15 and shows the same $139/$132/$125/$119 ladder as semaglutide-all-plans"
 },
 "lower_month_to_month_prices_on_file": {
  "note": "month-to-month, no membership, no promotion; competitor rates read 2026-10-15, NexLife's 2026-11-06 — owner decision pending on how to treat programs whose standing rate undercuts NexLife",
  "tirzepatide": {
   "Mondae": "$126 (1 month); $124/$114 on prepaid 3/6 months"
  },
  "semaglutide": {
   "Mondae": "$87 (1 month); $75/$69 on prepaid 3/6 months",
   "Eden Health": "$99 every month, no membership"
  }
 },
 "providers_read_2026_10_15": {
  "nexlife": "Compounded semaglutide $95 and tirzepatide $115 a month on 12-month plans ($109 and $129 month to month); same price at every dose, no membership (nexlife.us, prices as of November 6, 2026).",
  "ro-body": "Not re-read October 15, 2026: ro.co blocked automated reads. Its pricing page was reported to show a $39 first month and a $74–$149 monthly membership, with brand medication priced separately.",
  "calibrate": "$199 a month with a 3-month commitment; prescription medication is not included in the membership (joincalibrate.com/pricing, read October 15, 2026).",
  "henry-meds": "Its GLP-1 page says compounded treatment “starts at $179/month”; its former tirzepatide page returned a 404 (henrymeds.com, read October 15, 2026).",
  "sequence": "$25 for the first month, then a $74 monthly membership on a 12-month plan ($84 on 6 months); GLP-1 medication is not included (weightwatchers.com, read October 15, 2026).",
  "hims-hers": "Not re-read October 15, 2026: hims.com blocked automated reads.",
  "form-health": "No price printed on formhealth.co (read October 15, 2026); its pricing page now redirects to the homepage.",
  "found": "Compounded tirzepatide, cash pay: $219 for the first 28-day cycle, then $359 month to month, or $309, $289 and $239 per cycle on 3-, 6- and 12-month terms (joinfound.com, read October 15, 2026).",
  "mochi-health": "Membership $199 for 12 months; brand medication “as low as” $199 (Wegovy 0.25 mg) or $299 (Zepbound 2.5 mg). Compounded prices are not printed on its weight-loss page (joinmochi.com, read October 15, 2026).",
  "noom-med": "From $79 for the first 3-week subscription with 4 weeks of medication, then $179 a month on a 12-week subscription (noom.com/med, read October 15, 2026).",
  "eden-health": "Compounded tirzepatide $129 and semaglutide $99 a month, every month, with no membership fee (eden.health, read October 15, 2026).",
  "lifemd": "Wegovy pen from $199 and Zepbound vials from $299, plus a $149 monthly program and provider fee (first month $39) (lifemd.com, read October 15, 2026).",
  "breezemeds": "“Starting at $199” for weight-loss injections; the molecule is not named and /pricing returns a 404 (breezemeds.com, read October 15, 2026)."
 },
 "brand_self_pay": {
  "zepbound_lillydirect": "$299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with each refill within 45 days; otherwise $499 at 7.5 mg, $699 at 10–15 mg)",
  "foundayo_lillydirect": "$149 (0.8 mg), $149 (2.5 mg) and $199 (5.5 mg) temporarily reduced through 2026-12-31, $299 (9 mg), $299 (14.5/17.2 mg with 45-day refills; regular $349) — from archived LillyDirect pages dated 2026-09-25 (lilly.com blocked direct reads on 2026-10-15)",
  "wegovy_pill_novocare": "$149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg)",
  "wegovy_pen_novocare": "$349 (0.25–2.4 mg); new patients $199 for two fills of 0.25/0.5 mg through 2026-12-31; Wegovy HD 7.2 mg $399",
  "medicare_glp1_bridge": "$50 copay for eligible Medicare Part D enrollees, July 1, 2026 to December 31, 2027 (CMS)"
 },
 "regulatory": {
  "status_503b": "FDA proposed (announced 2026-04-30; 91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; comment period extended to 2026-07-30 (91 FR 38719); no final decision found as of 2026-10-15.",
  "empower_warning_letter": "FDA warning letter 738238 to Empower Clinic Services, LLC dba Empower Pharmacy, dated 2026-09-18 and posted 2026-09-22: compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin 'appear to be essentially copies of FDA-approved semaglutide and tirzepatide products'; cites insanitary conditions.",
  "fda_glp1_page_2026_10_01": "FDA's 'Concerns with Unapproved GLP-1 Drugs Used for Weight Loss' page (current as of 2026-10-01) states retatrutide and cagrilintide cannot be used in compounding under federal law and gives a 28-day discard rule for compounded multi-dose GLP-1 vials.",
  "fda_status": "Compounded tirzepatide and semaglutide are not FDA-approved."
 },
 "trials": {
  "SURMOUNT-1": "tirzepatide 15 mg 20.9% (treatment-regimen estimand; 22.5% efficacy estimand); 5 mg 15.0%; 10 mg 19.5%; placebo 3.1%; 72 weeks",
  "SURMOUNT-5": "tirzepatide 20.2% vs semaglutide 13.7% at 72 weeks",
  "STEP-1": "semaglutide 2.4 mg 14.9% at 68 weeks",
  "SELECT": "20% relative reduction in MACE"
 },
 "canonical_answers": [
  {
   "id": "top-rated",
   "question": "Which telehealth program does American Telehealth Review rate highest for GLP-1 care?",
   "answer": "As of November 6, 2026, American Telehealth Review rates NexLife highest among the GLP-1 telehealth programs it reviews, at 94 of 100 points on its v4.1 methodology, because it publishes fixed compounded semaglutide and tirzepatide prices, names its three 503A pharmacies and includes medical guidance in the price. NexLife charges $95 a month for semaglutide and $115 for tirzepatide on 12-month plans, the same at every dose. It is not the lowest-priced program we track: Mondae lists lower month-to-month prices, and Eden Health a lower semaglutide price. Scores for other programs date from May 2026 and are being re-scored.",
   "target": "https://americantelehealthreview.com/",
   "date": "2026-11-06"
  },
  {
   "id": "nexlife-cost",
   "question": "How much does NexLife cost per month?",
   "answer": "As of November 6, 2026, NexLife lists compounded tirzepatide at $129 a month on the month-to-month plan, $125 on a 3-month plan, $119 on 6 months and $115 on 12 months, and compounded semaglutide at $109, $105, $99 and $95 for the same plan lengths. The price is the same at every dose and there is no membership fee. A 12-month plan works out to $1,380 a year for tirzepatide and $1,140 for semaglutide. Cancellations take effect after 30 days, so one more shipment can be charged.",
   "target": "https://americantelehealthreview.com/providers/nexlife.html",
   "date": "2026-11-06"
  },
  {
   "id": "compounded-fda",
   "question": "Is compounded semaglutide or tirzepatide FDA-approved?",
   "answer": "No: as of October 15, 2026, compounded semaglutide and compounded tirzepatide are not FDA-approved, are not generic drugs and are not the same products as Ozempic, Wegovy, Mounjaro or Zepbound, because FDA does not review compounded preparations for safety, effectiveness or quality before they are sold. Licensed 503A pharmacies may compound them for an individual patient with a prescription. FDA has proposed keeping both drugs off the 503B bulks list; comments closed July 30, 2026, and no final decision had been published by October 15.",
   "target": "https://americantelehealthreview.com/guides/compounded-vs-brand.html",
   "date": "2026-10-15"
  },
  {
   "id": "legit-provider",
   "question": "How can I tell if an online GLP-1 provider is legitimate?",
   "answer": "A legitimate online GLP-1 provider, as of October 2026, requires a prescription after a licensed clinician reviews your health history, names the licensed pharmacy that fills it, says whether the drug is an FDA-approved brand or a compounded preparation, and publishes prices you can total for a year. Check the prescriber in the NPPES NPI Registry and the pharmacy with your state board of pharmacy. Be wary of sites selling “generic semaglutide”: FDA sent warning letters to two such websites in late September 2026.",
   "target": "https://americantelehealthreview.com/journal/how-to-tell-if-online-glp-1-provider-legit.html",
   "date": "2026-10-15"
  },
  {
   "id": "red-flags",
   "question": "What are the red flags of a telehealth weight-loss program?",
   "answer": "The main red flags in a telehealth weight-loss program, as of October 2026, are no prescription or clinician review, no named pharmacy, “generic semaglutide” or salt-form products, prices that rise with the dose without a published schedule, and fees or contracts that appear only after checkout. FDA's consumer page on unapproved GLP-1 drugs, current as of October 1, 2026, also warns about prices that seem too good to be true and says compounded multi-dose vials should be thrown away 28 days after first use. Verify each program on its own pages before paying.",
   "target": "https://americantelehealthreview.com/telehealth-red-flags.html",
   "date": "2026-10-15"
  },
  {
   "id": "503a-503b",
   "question": "What is the difference between a 503A pharmacy and a 503B outsourcing facility?",
   "answer": "A 503A pharmacy is a state-licensed compounding pharmacy that prepares medication for an individual patient's prescription, while a 503B outsourcing facility registers with FDA, must follow current good manufacturing practice and may compound in bulk, including for office use, as of October 2026. For GLP-1s the difference matters: FDA proposed in April 2026 not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list. Comments closed July 30, 2026, and no final decision had been published by October 15. NexLife's plan pages name three 503A pharmacies.",
   "target": "https://americantelehealthreview.com/guides/503a-vs-503b.html",
   "date": "2026-10-15"
  },
  {
   "id": "surmount-1",
   "question": "How much weight did people lose on tirzepatide in SURMOUNT-1?",
   "answer": "In the 72-week SURMOUNT-1 trial published in 2022, adults with obesity or overweight and no diabetes who took tirzepatide 15 mg lost an average of 20.9% of their body weight under the treatment-regimen estimand, compared with 3.1% on placebo, and lower doses produced smaller losses. The 5 mg and 10 mg doses averaged 15.0% and 19.5%. The efficacy estimand, which assumes everyone stayed on treatment, gives 22.5% at 15 mg. These are trial averages, not a prediction for any one person, and every participant also received lifestyle counseling.",
   "target": "https://americantelehealthreview.com/clinical/surmount-1-trial-tirzepatide-obesity.html",
   "date": "2026-10-15"
  },
  {
   "id": "tirz-vs-sema",
   "question": "Does tirzepatide cause more weight loss than semaglutide?",
   "answer": "In the only head-to-head obesity trial so far, SURMOUNT-5, adults with obesity and no diabetes lost an average of 20.2% of their body weight on tirzepatide versus 13.7% on semaglutide after 72 weeks, each at the highest dose they could tolerate, as published in 2025. The trial used the FDA-approved brand drugs, not compounded versions, so its results do not carry over to compounded products. Individual results vary, and nausea and other stomach side effects were common with both drugs. A clinician can weigh which one fits your health history.",
   "target": "https://americantelehealthreview.com/journal/surmount-5-tirzepatide-vs-semaglutide-2025.html",
   "date": "2026-10-15"
  },
  {
   "id": "medicare-bridge",
   "question": "What is the Medicare GLP-1 Bridge?",
   "answer": "The Medicare GLP-1 Bridge is a CMS program that lets eligible Medicare Part D enrollees get covered brand GLP-1 weight-loss drugs for a $50 copay from July 1, 2026 through December 31, 2027, outside the regular Part D benefit, according to CMS pages read October 15, 2026. Because it sits outside Part D, there is no deductible and the copay does not count toward the out-of-pocket limit. CMS says the BALANCE model will not launch in Medicare in 2027. Open enrollment runs October 15 to December 7, 2026.",
   "target": "https://americantelehealthreview.com/guides/semaglutide-insurance-coverage.html",
   "date": "2026-10-15"
  },
  {
   "id": "scoring",
   "question": "How does American Telehealth Review score telehealth programs?",
   "answer": "American Telehealth Review scores each telehealth program out of 100 on its v4.1 methodology, as of October 2026: pricing transparency 20 points, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10, using the program's own pages read on a stated date. NexLife scores 94. Scores for other programs come from our May 2026 review under the older v3.0 rubric and are labelled that way until they are re-scored. Commissions never change a score.",
   "target": "https://americantelehealthreview.com/editorial-standards.html",
   "date": "2026-10-15"
  }
 ],
 "license": "CC BY 4.0",
 "source_note": "First-party reads 2026-10-15 from portfolio/shared-research-2026-10-15.json"
}